KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Capital Employed: 2011-2025

Historic Return on Capital Employed for Nektar Therapeutics (NKTR) over the last 14 years, with Sep 2025 value amounting to -0.52%.

  • Nektar Therapeutics' Return on Capital Employed rose 7.00% to -0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.52%, marking a year-over-year increase of 7.00%. This contributed to the annual value of -0.36% for FY2024, which is 16.00% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' Return on Capital Employed is -0.52%, which was up 16.94% from -0.63% recorded in Q2 2025.
  • Over the past 5 years, Nektar Therapeutics' Return on Capital Employed peaked at -0.29% during Q1 2021, and registered a low of -0.71% during Q4 2023.
  • Over the past 3 years, Nektar Therapeutics' median Return on Capital Employed value was -0.59% (recorded in 2024), while the average stood at -0.58%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first declined by 25bps in 2022, then rose by 28bps in 2024.
  • Nektar Therapeutics' Return on Capital Employed (Quarterly) stood at -0.40% in 2021, then declined by 15bps to -0.56% in 2022, then dropped by 16bps to -0.71% in 2023, then increased by 28bps to -0.43% in 2024, then grew by 7bps to -0.52% in 2025.
  • Its Return on Capital Employed stands at -0.52% for Q3 2025, versus -0.63% for Q2 2025 and -0.55% for Q1 2025.